Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author BARBOSA, Joao Arthur B. A. FMUSP-HC
ANTUNES, Alberto Azoubel FMUSP-HC
dc.date.issued 2013
dc.identifier.citation UROLOGY, v.82, n.1, p.182-188, 2013
dc.identifier.issn 0090-4295
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/1695
dc.description.abstract OBJECTIVE To evaluate the association of male lower urinary tract symptoms (LUTS) with metabolic syndrome (MetS) and androgenetic alopecia in a Latin American population. METHODS We enrolled 907 patients for prospective evaluation at a single institution. LUTS were evaluated with the International Prostate Symptom Score (IPSS). Subjects were evaluated with respect to hypertension, diabetes, dyslipidemia, previous cardiovascular events, body mass index (BMI), waist and hip circumference, and a laboratorial investigation including prostate-specific antigen (PSA), C-reactive protein (CRP), and gonadal steroids. Alopecia was classified according to the Norwood-Hamilton scale. RESULTS Mean patient age was 61.0 years; 57.5% of subjects had moderate/severe LUTS; MetS was present in 17.2% of subjects and 53.9% were classified as bald. Age, hypertension, diabetes, dyslipidemia, alopecia, previous cardiovascular event, and elevated waist-to-hip ratio (WHR) were associated with moderate/severe LUTS and with storage symptoms (P < .05). On multivariable analysis, age (odds ratio [OR] 2.30, 95% confidence interval [CI] 1.63-3.25), cardiovascular events (OR 1.73, 95% CI 1.07-2.78), and WHR (OR 1.65, 95% CI 1.13-2.40) were independent predictors for LUTS. For storage symptoms, age (OR 1.80, 95% CI 1.28-2.54), cardiovascular event (OR 2.07, 95% CI 1.27-3.39), WHR (OR 1.54, 95% CI 1.06-2.25), and MetS (OR 1.70, 95% CI 1.01-2.86) were independent risk factors. Age and cardiovascular event were the only independent predictors for voiding symptoms. CONCLUSION Components of the MetS were strongly associated with moderate and severe LUTS. WHR and cardiovascular events were independent predictors of voiding and storage symptoms, and MetS was an independent predictor of storage symptoms. Alopecia was not an independent predictor of LUTS. UROLOGY 82: 182-188, 2013. (C) 2013 Elsevier Inc.
dc.language.iso eng
dc.relation.ispartof Urology
dc.rights restrictedAccess
dc.subject.other benign prostatic hyperplasia; male pattern baldness; steroid-hormones; men; association; health; neurodegeneration; dutasteride; finasteride; prevalence
dc.title Risk Factors for Male Lower Urinary Tract Symptoms: The Role of Metabolic Syndrome and Androgenetic Alopecia in a Latin American Population
dc.type article
dc.rights.holder Copyright ELSEVIER SCIENCE INC
dc.description.group LIM/55
dc.identifier.doi 10.1016/j.urology.2013.03.001
dc.identifier.pmid 23642850
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author BARBOSA, Joao Arthur B. A.:FM:
hcfmusp.author MURACCA, Eduardo:HC:ICHC
hcfmusp.author NAKANO, Elcio:HC:ICHC
hcfmusp.author PARANHOS, Mario:HC:ICHC
hcfmusp.author NATALINO, Renato:FM:
hcfmusp.author CORDEIRO, Paulo:HC:ICHC
hcfmusp.author SROUGI, Miguel:FM:MCG
hcfmusp.author ANTUNES, Alberto Azoubel:HC:LIM/55
hcfmusp.origem.id WOS:000321036200049
hcfmusp.origem.id 2-s2.0-84879553884
hcfmusp.publisher.city NEW YORK
hcfmusp.publisher.country USA
hcfmusp.relation.reference · Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
· Arias-Santiago S, 2012, J AM ACAD DERMATOL, V66, P401, DOI 10.1016/j.jaad.2010.12.023
· Arias-Santiago S, 2010, J AM ACAD DERMATOL, V63, P420, DOI 10.1016/j.jaad.2009.10.018
· Azadzoi KM, 2007, J UROLOGY, V178, P710, DOI 10.1016/j.juro.2007.03.096
· Cellek S, 1999, BRIT J PHARMACOL, V128, P1804, DOI 10.1038/sj.bjp.0702981
· Chen WC, 2004, ARCH DERMATOL RES, V296, P245, DOI 10.1007/s00403-004-0514-z
· Gao Y, 2012, UROLOGY, V79, P194, DOI 10.1016/j.urology.2011.07.1399
· Guarrera M, 2009, Int J Trichology, V1, P120, DOI 10.4103/0974-7753.58554
· Gupta A, 2006, UROLOGY, V68, P1198, DOI 10.1016/j.urology.2006.09.034
· Hammarsten J, 2001, EUR UROL, V39, P151, DOI 10.1159/000052430
· Jin B, 1999, J CLIN ENDOCR METAB, V84, P3613, DOI 10.1210/jc.84.10.3613
· Kupelian V, 2013, J UROLOGY, V189, pS107, DOI 10.1016/j.juro.2012.11.026
· Lee RK, 2012, BJU INT, V110, P540, DOI 10.1111/j.1464-410X.2011.10819.x
· Montorsi F, 2011, BJU INT, V107, P1426, DOI 10.1111/j.1464-410X.2011.10129.x
· Neuhouser ML, 2004, UROLOGY, V64, P201, DOI 10.1016/j.urology.2004.04.025
· Nickel JC, 2011, BJU INT, V108, P388, DOI 10.1111/j.1464-410X.2011.10195.x
· NORWOOD OT, 1975, SOUTHERN MED J, V68, P1359
· Oh BR, 1998, UROLOGY, V51, P744, DOI 10.1016/S0090-4295(98)00108-3
· Ohgaki K, 2011, UROLOGY, V77, P1432, DOI 10.1016/j.urology.2010.12.024
· Rohrmann S, 2005, INT J OBESITY, V29, P310, DOI 10.1038/sj.ijo.0802881
· Rossi A, 2011, DERMATOL THER, V24, P455, DOI 10.1111/j.1529-8019.2011.01441.x
· Severi G, 2003, BRIT J DERMATOL, V149, P1207, DOI 10.1111/j.1365-2133.2003.05565.x
· Shenfeld OZ, 2005, UROLOGY, V65, P181, DOI 10.1016/j.urology.2004.08.055
· Su LH, 2010, BRIT J DERMATOL, V163, P371, DOI 10.1111/j.1365-2133.2010.09816.x
· Temml C, 2009, UROLOGY, V73, P544, DOI 10.1016/j.urology.2008.10.027
· Vignozzi L, 2012, J ENDOCRINOL, V212, P71, DOI 10.1530/JOE-11-0289
· Yang TK, 2012, UROLOGY, V80, P1093, DOI 10.1016/j.urology.2012.08.002
· Yip L, 2011, AUSTRALAS J DERMATOL, V52, P81, DOI 10.1111/j.1440-0960.2011.00745.x
· Zhu YS, 2009, ANN NY ACAD SCI, V1155, P43, DOI 10.1111/j.1749-6632.2009.04115.x
dc.description.index MEDLINE
hcfmusp.citation.scopus 9
hcfmusp.citation.wos 10

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


My Account